Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 2, facilitated glucose transporter member 9 (SLC2A9), commonly known as GLUT9, is a voltage-sensitive, high-capacity urate transporter primarily expressed in the kidneys, liver, and intestine. Although structurally related to the facilitative glucose transporter family, its primary physiological substrate is uric acid (urate), which it transports at rates significantly faster than hexoses. GLUT9 plays a critical role in maintaining systemic uric acid homeostasis by mediating the reabsorption of urate from the renal proximal tubules back into the bloodstream. Dysregulation or genetic variations in SLC2A9 are strongly associated with hyperuricemia, gout, and nephrolithiasis, while loss-of-function mutations cause hereditary renal hypouricemia type 2, which predisposes individuals to exercise-induced acute kidney injury. Consequently, GLUT9 is a major therapeutic target for uricosuric drugs designed to lower serum uric acid levels in patients with gout and hyperuricemia. Pharmacological inhibitors of GLUT9, including traditional uricosuric agents like benzbromarone and probenecid, as well as novel selective inhibitors like JTT-763, block urate reabsorption to promote urinary excretion, though therapeutic development must carefully balance efficacy with the risk of renal stones and acute kidney injury.
Inhibition of SLC2A9/GLUT9-mediated urate transport to block renal reabsorption and promote urinary excretion of uric acid
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 9 (GLUT9).